Sub-femto-g free fall for space-based gravitational wave observatories: LISA pathfinder results

We report the first results of the LISA Pathfinder in-flight experiment. The results demonstrate that two free-falling reference test masses, such as those needed for a space-based gravitational wave observatory like LISA, can be put in free fall with a relative acceleration noise with a square root of the power spectral density of 5.2 ± 0.1 fm s−2/√Hz or (0.54 ± 0.01) × 10−15 g/√Hz, with g the standard gravity, for frequencies between 0.7 and 20 mHz. This value is lower than the LISA Pathfinder requirement by more than a factor 5 and within a factor 1.25 of the requirement for the LISA mission, and is compatible with Brownian noise from viscous damping due to the residual gas surrounding the test masses. Above 60 mHz the acceleration noise is dominated by interferometer displacement readout noise at a level of (34.8 ± 0.3) fm/√Hz, about 2 orders of magnitude better than requirements. At f ≤ 0.5 mHz we observe a low-frequency tail that stays below 12 fm s−2/√Hz down to 0.1 mHz. This performance would allow for a space-based gravitational wave observatory with a sensitivity close to what was originally foreseen for LISA

Challenges and opportunities of gravitational-wave searches at MHz to GHz frequencies

The first direct measurement of gravitational waves by the LIGO and Virgo collaborations has opened up new avenues to explore our Universe. This white paper outlines the challenges and gains expected in gravitational-wave searches at frequencies above the LIGO/Virgo band, with a particular focus on Ultra High-Frequency Gravitational Waves (UHF-GWs), covering the MHz to GHz range. The absence of known astrophysical sources in this frequency range provides a unique opportunity to discover physics beyond the Standard Model operating both in the early and late Universe, and we highlight some of the most promising gravitational sources. We review several detector concepts that have been proposed to take up this challenge, and compare their expected sensitivity with the signal strength predicted in various models. This report is the summary of the workshop “Challenges and opportunities of high-frequency gravitational wave detection” held at ICTP Trieste, Italy in October 2019, that set up the stage for the recently launched Ultra-High-Frequency Gravitational Wave (UHF-GW) initiative

LISA pathfinder performance confirmed in an open-loop configuration: Results from the free-fall actuation mode

We report on the results of the LISA Pathfinder (LPF) free-fall mode experiment, in which the control force needed to compensate the quasistatic differential force acting on two test masses is applied intermittently as a series of "impulse" forces lasting a few seconds and separated by roughly 350 s periods of true free fall. This represents an alternative to the normal LPF mode of operation in which this balancing force is applied continuously, with the advantage that the acceleration noise during free fall is measured in the absence of the actuation force, thus eliminating associated noise and force calibration errors. The differential acceleration noise measurement presented here with the free-fall mode agrees with noise measured with the continuous actuation scheme, representing an important and independent confirmation of the LPF result. An additional measurement with larger actuation forces also shows that the technique can be used to eliminate actuation noise when this is a dominant factor. © 2019 authors. Published by the American Physical Society

Sensor noise in LISA Pathfinder: Laser frequency noise and its coupling to the optical test mass readout

The LISA Pathfinder (LPF) mission successfully demonstrated the feasibility of the technology needed for the future space borne gravitational wave observatory LISA. A key subsystem under study was the laser interferometer, which measured the changes in relative distance in between two test masses (TMs). It achieved a sensitivity of 32.0+2.4−1.7  fm/√Hz, which was significantly better than the prelaunch tests. This improved performance allowed direct observation of the influence of laser frequency noise in the readout. The differences in optical path lengths between the measurement and reference beams in the individual interferometers of our setup determined the level of this undesired readout noise. Here, we discuss the dedicated experiments performed on LPF to measure these differences with high precision. We reached differences in path length difference between (368±5)  μm and (329.6±0.9)  μm which are significantly below the required level of 1 mm or 1000  μm. These results are an important contribution to our understanding of the overall sensor performance. Moreover, we observed varying levels of laser frequency noise over the course of the mission. We provide evidence that these do not originate from the laser frequency stabilization scheme which worked as expected. Therefore, this frequency stabilization would be applicable to other missions with similar laser frequency stability requirements

First cross-correlation analysis of interferometric and resonant-bar gravitational-wave data for stochastic backgrounds

Data from the LIGO Livingston interferometer and the ALLEGRO resonant-bar detector, taken during LIGO's fourth science run, were examined for cross correlations indicative of a stochastic gravitational-wave background in the frequency range 850-950 Hz, with most of the sensitivity arising between 905 and 925 Hz. ALLEGRO was operated in three different orientations during the experiment to modulate the relative sign of gravitational-wave and environmental correlations. No statistically significant correlations were seen in any of the orientations, and the results were used to set a Bayesian 90% confidence level upper limit of Ωgw(f)≤1.02, which corresponds to a gravitational-wave strain at 915 Hz of 1.5×10-23Hz-1/2. In the traditional units of h1002Ωgw(f), this is a limit of 0.53, 2 orders of magnitude better than the previous direct limit at these frequencies. The method was also validated with successful extraction of simulated signals injected in hardware and software. © 2007 The American Physical Society

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Step (satellite test of the equivalence principle)

STEP is one of a number of missions now being developed to take advantage of the quiet space environment to carry out very sensitive gravitational experiments. Using pairs of concentric free-falling proof-masses, STEP will be able to test the equivalence principle (EP) to a sensitivity at least five orders of magnitude better than currently achievable on ground. The EP is a founding principle of general relativity and STEP is the most sensitive experiment of this type planned so far, aiming at 1 part in 1018. 2007 Published by Elsevier Ltd on behalf of COSPAR